The Global BCG Vaccine Market size is estimated at USD 104.84 million in 2023 and is expected to reach USD 175.63 million by 2032, growing at a CAGR of 5.9% during the forecast period (2024-2032).
This surge is fueled by factors such as the prevalence of tuberculosis, advancements in vaccine research and development, and governmental initiatives promoting vaccination campaigns. This article explores the market dynamics, the impact of the COVID-19 pandemic, age group differentials, applications, distribution channels, regional insights, and the competitive landscape within the BCG vaccine market.
BCG Vaccine Market Overview
Factors Driving Growth
- Prevalence of Tuberculosis: Tuberculosis, ranking 13th in global mortality, is a key driver, with an anticipated 10.6 million cases in 2021.
- Technological Advancements: Advances in vaccine research and development contribute to the market’s upward trajectory.
- Government Initiatives: Increased governmental initiatives globally to combat tuberculosis through vaccination campaigns.
Impact of COVID-19
The initial impact of the COVID-19 pandemic resulted in a substantial decline in demand for the BCG vaccine due to strict lockdowns and reduced healthcare facility visits. Manufacturing prioritization of COVID-19 vaccines also led to shortages in BCG vaccines. However, the market is expected to rebound as the pandemic is gradually brought under control.
Age Group Insights
- Pediatrics Leading the Charge
The market is segmented into adults and pediatrics. In 2022, the pediatrics segment dominated, driven by children’s susceptibility to tuberculosis, especially in developing countries. Pediatric tuberculosis accounted for approximately 31% of the global burden, intensifying the demand for pediatric BCG vaccines.
Application Insights
The BCG vaccine market is segmented by application into bladder cancer and tuberculosis. The tuberculosis segment held the majority share in 2022 due to the rising global prevalence of tuberculosis. Government initiatives, such as India’s TB Report 2022, emphasize the severity of pediatric tuberculosis, further propelling BCG vaccination rates.
Distribution Channel Insights
- Retail Pharmacies at the Helm
The distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies. In 2022, retail pharmacies led the market, offering personalized advice and attracting buyers. Their role in managing complicated ailments like tuberculosis and bladder cancer contributes to their market dominance.
Regional Insights
Asia Pacific emerged as the dominant region in 2022. Factors contributing to this dominance include the rise in TB cases, increased immunization programs, major players investing in BCG vaccine development, and government funding in healthcare. The vulnerability to tuberculosis due to factors like homelessness and poverty also contributes to the market’s growth in countries like India and China.
Competitive Landscape
Key Players and Strategic Initiatives
- Major players in the BCG vaccine market include Serum Institute of India Pvt. Ltd., Microgen, Merck & Co., Inc., Japan BCG Laboratory, and AJ Biologics Sdn Bhd. These players engage in strategic initiatives such as product launches, collaborations, mergers, and acquisitions. Notable instances include the WHO’s launch of the “TB Vaccine Accelerator Council” and the Serum Institute of India seeking emergency use authorization for its recombinant BCG vaccine.
Global BCG Vaccine Market Report Segmentation
Type Outlook (Revenue, USD Million, 2018 – 2032)
- Subunit Vaccines
- Recombinant vaccines
- Conjugate Vaccines
- Toxoid vaccines
- Inactivated
- Live Attenuated
- mRNA vaccines
- Viral vector vaccines
Route Of Administration Outlook (Revenue, USD Million, 2018 – 2032)
- Oral
- Parenteral
- Nasal
Disease Indication Outlook (Revenue, USD Million, 2018 – 2032)
- Viral Diseases
- Hepatitis
- Influenza
- MMR
- Rotavirus
- Covid-19
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal Diseases
- DPT
- Cancer Vaccines
- Allergy Vaccines
Age Group Outlook (Revenue, USD Million, 2018 – 2032)
- Pediatric
- Adult
Distribution Channel Outlook (Revenue, USD Million, 2018 – 2032)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
Regional Outlook (Revenue, USD Million, 2018 – 2032)
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- New Zealand
- Latin America
- Middle East and Africa (MEA)
BCG Vaccine Market Report Scope |
| Report Attribute | Details |
| Market Size Value in 2023 | USD 104.84 Million |
| Revenue Forecast in 2032 | USD 175.63 Million |
| Growth Rate | CAGR of 5.9% from 2024 to 2032 |
| Base Year for estimation | 2023 |
| Historical Data | 2018 – 2023 |
| Forecast Period | 2024. – 2032 |
| Report Updated | Feb-24 |
| Quantitative Units | Revenue in USD million and CAGR from 2024 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Type, Route Of Administration, Disease Indication, Age Group, Distribution Channel, and Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country Scope | U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key Companies Profiled | Serum Institute of India Pvt. Ltd., Microgen, Merck & Co., Inc., Japan BCG Laboratory, AJ Biologics Sdn Bhd, and Others. |
Conclusion
As the global BCG vaccine market rides the waves of technological innovation, increasing awareness, and strategic collaborations, it stands resilient against challenges posed by the COVID-19 pandemic. With a focus on pediatric vaccination, addressing tuberculosis, and expanding market avenues, the BCG vaccine market is poised for sustained growth in the coming years.
Table of Contents
Chapter 1. Methodology And Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Secondary Sources
1.3.3. Primary Research
1.4. Information Or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.7. List Of Secondary Sources
1.8. List Of Abbreviations
1.9. List Of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type and Route of Administration Snapshot
2.3. Disease Indication and Distribution Channel Snapshot
2.4. Age Group Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Restraint Analysis
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.7. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Vaccine Market: Type Movement Analysis
4.2. Subunit Vaccines
4.2.1. Vaccine Market For Subunit Vaccines, 2018 – 2032 (USD Billion)
4.2.2. Recombinant vaccines
4.2.2.1. Vaccine Market For Recombinant Vaccines, 2018 – 2032 (USD Billion)
4.2.3. Conjugate Vaccines
4.2.3.1. Vaccine Market For Conjugate Vaccines, 2018 – 2032 (USD Billion)
4.2.4. Toxoid vaccines
4.2.4.1. Vaccine Market For Toxoid Vaccines, 2018 – 2032 (USD Billion)
4.3. Inactivated
4.3.1. Vaccine Market For Inactivated, 2018 – 2032 (USD Billion)
4.4. Live Attenuated
4.4.1. Vaccine Market For Live Attenuated, 2018 – 2032 (USD Billion)
4.5. mRNA vaccines
4.5.1. Vaccine Market For mRNA vaccines, 2018 – 2032 (USD Billion)
4.6. Viral vector vaccines
4.6.1. Vaccine Market For Viral Vector Vaccines, 2018 – 2032 (USD Billion)
Chapter 5. Route Of Administration Business Analysis
5.1. Vaccine Market: Route of Administration Movement Analysis
5.2. Oral
5.2.1. Vaccine Market For Oral, 2018 – 2032 (USD Billion)
5.3. Parenteral
5.3.1. Vaccine Market For Parenteral, 2018 – 2032 (USD Billion)
5.4. Nasal
5.4.1. Vaccine Market For Nasal, 2018 – 2032 (USD Billion)
Chapter 6. Disease Indication Business Analysis
6.1. Vaccine Market: Disease Indication Movement Analysis
6.2. Viral Diseases
6.2.1. Vaccine Market For Viral Diseases, 2018 – 2032 (USD Billion)
6.2.2. Hepatitis
6.2.2.1. Vaccine Market For Hepatitis, 2018 – 2032 (USD Billion)
6.2.3. Influenza
6.2.3.1. Vaccine Market For Influenza, 2018 – 2032 (USD Billion)
6.2.4. HPV
6.2.4.1. Vaccine Market For HPV, 2018 – 2032 (USD Billion)
6.2.5. MMR
6.2.5.1. Vaccine Market For MMR, 2018 – 2032 (USD Billion)
6.2.6. Rotavirus
6.2.6.1. Vaccine Market For Rotavirus, 2018 – 2032 (USD Billion)
6.2.7. Herpes Zoster
6.2.7.1. Vaccine Market For Herpes Zoster, 2018 – 2032 (USD Billion)
6.2.8. Covid-19
6.2.8.1. Vaccine Market For Covid-19, 2018 – 2032 (USD Billion)
6.2.9. Others
6.2.9.1. Vaccine Market For Others, 2018 – 2032 (USD Billion)
6.3. Bacterial Vaccines
6.3.1. Vaccine Market For Bacterial Vaccines, 2018 – 2032 (USD Billion)
6.3.2. Meningococcal Diseases
6.3.2.1. Vaccine Market For Meningococcal Diseases, 2018 – 2032 (USD Billion)
6.3.3. Pneumococcal Diseases
6.3.3.1. Vaccine Market For Pneumococcal Diseases, 2018 – 2032 (USD Billion)
6.3.4. DPT
6.3.4.1. Vaccine Market For DPT, 2018 – 2032 (USD Billion)
6.3.5. Others
6.3.5.1. Vaccine Market For Others, 2018 – 2032 (USD Billion)
6.4. Cancer Vaccines
6.4.1. Vaccine Market For Cancer Vaccines, 2018 – 2032 (USD Billion)
6.5. Allergy Vaccines
6.5.1. Vaccine Market For Allergy Vaccines, 2018 – 2032 (USD Billion)
Chapter 7. Age Group Business Analysis
7.1. Vaccine Market: Age Group Movement Analysis
7.2. Pediatric
7.2.1. Vaccine Market For Pediatric, 2018 – 2032 (USD Billion)
7.3. Adult
7.3.1. Vaccine Market For Adults, 2018 – 2032 (USD Billion)
Chapter 8. Distribution Channel Business Analysis
8.1. Vaccine Market: Distribution Channel Movement Analysis
8.2. Hospital & Retail Pharmacies
8.2.1. Vaccine Market For Hospital & Retail Pharmacies, 2018 – 2032 (USD Billion)
8.3. Government Suppliers
8.3.1. Vaccine Market For Government Suppliers 2018 – 2032 (USD Billion)
8.4. Others
8.4.1. Vaccine Market For Others, 2018 – 2032 (USD Billion)
Chapter 9. Regional Business Analysis
9.1. Vaccine Market Share By Region, 2022 & 2032
9.2. North America
9.2.1. North America Vaccines Market 2018 – 2032 (USD Billion)
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. Regulatory Framework
9.2.2.5. Reimbursement Scenario
9.2.2.6. U.S. Vaccine Market 2018 – 2032 (USD Billion)
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. Reimbursement Scenario
9.2.3.6. Canada Vaccine Market 2018 – 2032 (USD Billion)
9.3. Europe
9.3.1. Europe Vaccines Market 2018 – 2032 (USD Billion)
9.3.2. Germany
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. Regulatory Framework
9.3.2.5. Reimbursement Scenario
9.3.2.6. Germany Vaccine Market 2018 – 2032 (USD Billion)
9.3.3. UK
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. Reimbursement Scenario
9.3.3.6. UK Vaccine Market 2018 – 2032 (USD Billion)
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Reimbursement Scenario
9.3.4.6. France Vaccine Market 2018 – 2032 (USD Billion)
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. Reimbursement Scenario
9.3.5.6. Italy Vaccine Market 2018 – 2032 (USD Billion)
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Reimbursement Scenario
9.3.6.6. Spain Vaccine Market 2018 – 2032 (USD Billion)
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Reimbursement Scenario
9.3.7.6. Denmark Vaccine Market 2018 – 2032 (USD Billion)
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Reimbursement Scenario
9.3.8.6. Sweden Vaccine Market 2018 – 2032 (USD Billion)
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Reimbursement Scenario
9.3.9.6. Norway Vaccine Market 2018 – 2032 (USD Billion)
9.4. Asia Pacific
9.4.1. Asia Pacific Vaccine Market, 2018 – 2032 (USD Billion)
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Regulatory Framework
9.4.2.5. Reimbursement Scenario
9.4.2.6. Japan Vaccine Market 2018 – 2032 (USD Billion)
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Reimbursement Scenario
9.4.3.6. China Vaccine Market 2018 – 2032 (USD Billion)
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. Reimbursement Scenario
9.4.4.6. India Vaccine Market 2018 – 2032 (USD Billion)
9.4.5. South Korea
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. Reimbursement Scenario
9.4.5.6. South Korea Vaccine Market 2018 – 2032 (USD Billion)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Reimbursement Scenario
9.4.6.6. Australia Vaccine Market 2018 – 2032 (USD Billion)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Reimbursement Scenario
9.4.7.6. Thailand Vaccine Market 2018 – 2032 (USD Billion)
9.5. Latin America
9.5.1. Latin America Vaccine Market, 2018 – 2032 (USD Billion)
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Regulatory Framework
9.5.2.5. Reimbursement Scenario
9.5.2.6. Brazil Vaccine Market 2018 – 2032 (USD Billion)
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Reimbursement Scenario
9.5.3.6. Mexico Vaccine Market 2018 – 2032 (USD Billion)
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Reimbursement Scenario
9.5.4.6. Argentina Vaccine Market 2018 – 2032 (USD Billion)
9.6. MEA
9.6.1. MEA Vaccine Market, 2018 – 2032 (USD Billion)
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. Regulatory Framework
9.6.2.5. Reimbursement Scenario
9.6.2.6. South Africa Vaccine Market 2018 – 2032 (USD Billion)
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. Reimbursement Scenario
9.6.3.6. Saudi Arabia Vaccine Market 2018 – 2032 (USD Billion)
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Reimbursement Scenario
9.6.4.6. UAE Vaccine Market 2018 – 2032 (USD Billion)
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. Reimbursement Scenario
9.6.5.6. Kuwait Vaccine Market 2018 – 2032 (USD Billion)
Chapter 10. Competitive Landscape
10.1. Participant’s overview
10.2. Financial performance
10.3. Participant categorization
10.3.1. Market Leaders
10.3.2. Vaccine Market Share Analysis, 2022
10.3.3. Company Profiles
10.3.3.1. Serum Institute of India Pvt. Ltd.
10.3.3.1.1. Company Overview
10.3.3.1.2. Financial Performance
10.3.3.1.3. Product Benchmarking
10.3.3.1.4. Strategic Initiatives
10.3.3.2. Seqirus
10.3.3.2.1. Company Overview
10.3.3.2.2. Financial Performance
10.3.3.2.3. Product Benchmarking
10.3.3.2.4. Strategic Initiatives
10.3.3.3. Sanofi
10.3.3.3.1. Company Overview
10.3.3.3.2. Financial Performance
10.3.3.3.3. Product Benchmarking
10.3.3.3.4. Strategic Initiatives
10.3.3.4. GSK Plc.
10.3.3.4.1. Company Overview
10.3.3.4.2. Financial Performance
10.3.3.4.3. Product Benchmarking
10.3.3.4.4. Strategic Initiatives
10.3.3.5. Merck & Co., Inc.
10.3.3.5.1. Company Overview
10.3.3.5.2. Financial Performance
10.3.3.5.3. Product Benchmarking
10.3.3.5.4. Strategic Initiatives
10.3.3.6. Pfizer Inc.
10.3.3.6.1. Company Overview
10.3.3.6.2. Financial Performance
10.3.3.6.3. Product Benchmarking
10.3.3.6.4. Strategic Initiatives
10.3.3.7. Moderna Inc.
10.3.3.7.1. Company Overview
10.3.3.7.2. Financial Performance
10.3.3.7.3. Product Benchmarking
10.3.3.7.4. Strategic Initiatives
10.3.3.8. Sinovac
10.3.3.8.1. Company Overview
10.3.3.8.2. Financial Performance
10.3.3.8.3. Product Benchmarking
10.3.3.8.4. Strategic Initiatives
10.3.3.9. BioNTech SE
10.3.3.9.1. Company Overview
10.3.3.9.2. Financial Performance
10.3.3.9.3. Product Benchmarking
10.3.3.9.4. Strategic Initiatives
10.3.3.10. AstraZeneca
10.3.3.10.1. Company Overview
10.3.3.10.2. Financial Performance
10.3.3.10.3. Product Benchmarking
10.3.3.10.4. Strategic Initiatives
10.3.4. Strategy Mapping
10.3.4.1. Expansion
10.3.4.2. Acquisition
10.3.4.3. Collaborations
10.3.4.4. Product/Service Launch
10.3.4.5. Partnerships
10.3.4.6. Others
Type Outlook (Revenue, USD Million, 2018 – 2032)
- Subunit Vaccines
- Recombinant vaccines
- Conjugate Vaccines
- Toxoid vaccines
- Inactivated
- Live Attenuated
- mRNA vaccines
- Viral vector vaccines
Route Of Administration Outlook (Revenue, USD Million, 2018 – 2030)
- Oral
- Parenteral
- Nasal
Disease Indication Outlook (Revenue, USD Million, 2018 – 2030)
- Viral Diseases
- Hepatitis
- Influenza
- MMR
- Rotavirus
- Covid-19
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal Diseases
- DPT
- Cancer Vaccines
- Allergy Vaccines
Age Group Outlook (Revenue, USD Million, 2018 – 2030)
- Pediatric
- Adult
Distribution Channel Outlook (Revenue, USD Million, 2018 – 2030)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
